NEUREN PHARMACEUTICALS LIMITED
Patent Owner
Stats
- 18 US PATENTS IN FORCE
- 1 US APPLICATIONS PENDING
- Jan 16, 2018 most recent publication
Details
- 18 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 282 Total Citation Count
- Nov 09, 1995 Earliest Filing
- 27 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2017/0020,869 Neuroprotective Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disordersJan 22, 16Jan 26, 17[A61K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9867823 Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disordersJan 22, 16Jan 16, 18[A61K]
9708366 Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamateJan 27, 12Jul 18, 17[A61K, C07K]
9212204 Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acidJan 26, 15Dec 15, 15[A61K, C07K]
9119851 Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animalsJun 25, 14Sep 01, 15[A61K, C07D]
8791117 Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animalsMar 08, 11Jul 29, 14[A61K, A01N, C07D]
8637567 Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acidOct 13, 10Jan 28, 14[A61K]
8519127 Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathySep 27, 10Aug 27, 13[C07D]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0258,091 CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALSAbandonedMay 29, 15Sep 17, 15[A61K]
2015/0224,164 TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUMATIC ACIDAbandonedFeb 09, 15Aug 13, 15[A61K]
2009/0304,700 CONFORMATION SPECIFIC ANTIBODIES THAT BIND TREFOIL FACTORSAbandonedJun 05, 09Dec 10, 09[A61K, G01N, A61P, C07K]
2008/0199,455 Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using sameAbandonedOct 03, 07Aug 21, 08[A61K, G01N, C07K]
2007/0224,165 Neuroprotective Effects of Gly-Pro-Glu Following Intravenous InfusionAbandonedOct 22, 04Sep 27, 07[A61K]
2007/0015,707 Neuroprotective effect of activin in animals exposed to hypoxia/ischemiaAbandonedJul 26, 06Jan 18, 07[A61K]
2007/0004,641 Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamateAbandonedDec 21, 05Jan 04, 07[A61K]
2006/0281,675 Somatogenic therapy using a 20kda placental variant of growth hormoneAbandonedAug 19, 04Dec 14, 06[A61K]
2006/0035,279 Anti-GPE antibodies, their uses and assays for weakly immunogenic moleculesAbandonedOct 22, 04Feb 16, 06[G01N, C07K]
6780848 Use of GPE to protect glial cells or non-dopaminergic cells from death from neural injury or diseaseExpiredJul 20, 01Aug 24, 04[A61K, C07K]
2004/0053,218 Functional proteomics using double phage display screeningAbandonedOct 06, 03Mar 18, 04[C12Q]
2003/0103,959 Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptorAbandonedJun 20, 02Jun 05, 03[A61K]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.